A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may also lead to dose reduction of chemotherapy and/or treatment delays in both chemotherapy and radiation therapy, diminishing the efficacy of therapy in the curative setting. In this setting, the use of hematopoietic growth factors may thus be beneficial.

中文翻译：

---

非小细胞肺癌治疗相关的骨髓毒性。

在非小细胞肺癌的治疗中使用越来越积极的疗法（有或没有放射疗法的化学疗法）的主要结果是对骨髓的不良影响，可能导致中性粒细胞减少，血小板减少和/或贫血。骨髓抑制或骨髓毒性还可能导致化学疗法的剂量减少和/或化学疗法和放射疗法中的治疗延迟，从而降低了在治愈环境中的治疗功效。在这种情况下，使用造血生长因子可能是有益的。